



## Diabetic Peripheral Neuropathy: An Updated Review Article for Healthcare Professionals

<sup>1</sup>-Saud Mutlaq Saud Al-Ruwais,<sup>2</sup>-Salman Mkazi Sulaiman Alshammri,<sup>3</sup>-  
Abdulmajeed Obaid Abdullah Alotaibi,<sup>4</sup>-Hissah Muteb Dakhilallah Albalawi,<sup>5</sup>-  
Nadyah Ali Azeb Al Shomrani,<sup>6</sup>-Hussen Bahws Saeed Alhsnani,<sup>7</sup>-Ghazi Waleed  
Serouji,<sup>8</sup>-Raid Ali Alzahrani,<sup>9</sup>-Heba Farhan Hussein Al-Anzi,<sup>10</sup>-Rahma Ibrahim  
Abdullah Daghriri,<sup>11</sup>-Raed Mubarak Alshaikhi

<sup>1</sup> Ksa, Ministry Of Health, Dawadmi General Hospital

<sup>2</sup> Ksa, Ministry Of Health, King Khalid General Hafr Albatin

<sup>3</sup> Ksa, Ministry Of Health, Albgadyah General Hospital

<sup>4</sup> Ksa, Ministry Of Health, Tabuk Health Cluster

<sup>5</sup> Ksa, Ministry Of Health, Health Control Center At Tabuk Airport

<sup>6</sup> Ksa, Ministry Of Health, Al-Laith General Hospital

<sup>7</sup> Ksa, Ministry Of Health, Al-Nwaibea Primary Health Center

<sup>8</sup> Ksa, Ministry Of Health, Al-Nwaibea Primary Health Center

<sup>9</sup> Ksa, Ministry Of Health, Hittin Health Center

<sup>10</sup> Ksa, Ministry Of Health, Prince Sultan Medical Military City

<sup>11</sup> Ksa, Ministry Of Health, King Abdullah Medical Complex

### Abstract:

**Background:** Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus, leading to sensory, motor, and autonomic dysfunction. It manifests pain, numbness, paresthesia, and progressive loss of protective sensation, increasing the risk of foot ulcers and amputations. The exact pathophysiology remains unclear, but metabolic, neurovascular, and inflammatory mechanisms contribute to nerve damage.

**Aim:** To provide healthcare professionals with an updated review of the epidemiology, pathophysiology, diagnosis, and management of DPN, highlighting early recognition and prevention strategies.

**Methods:** A comprehensive literature review was conducted using peer-reviewed studies on diabetic neuropathy. Epidemiological data, risk factors, diagnostic approaches, and therapeutic interventions were analyzed to provide an evidence-based update.

**Results:** DPN affects 50-66% of individuals with diabetes over their lifetime. Early diagnosis relies on clinical assessment, including small and large fiber testing and monofilament exams. Persistent hyperglycemia, oxidative stress, and inflammatory processes contribute to nerve damage. Tight glucose control in type 1 diabetes reduces DPN risk by up to 78%, whereas in type 2 diabetes, the benefit is more limited. Multimodal management, including glycemic control, lifestyle modifications, foot care, and symptomatic treatment, can reduce complications and improve patient outcomes.

**Conclusion:** DPN is a major cause of morbidity and disability in diabetic patients. Early diagnosis and intervention are critical to prevent complications. Comprehensive management strategies, incorporating glucose control, patient education, and targeted pharmacological treatments, are essential for reducing disease burden and improving quality of life.

**Keywords:** Diabetic Peripheral Neuropathy, Diabetes Mellitus, Neuropathic Pain, Glycemic Control, Foot Ulcers, Neurological Examination

**Introduction:**

Peripheral neuropathy refers to a diverse group of clinical conditions characterized by dysfunction of the peripheral nervous system [1]. Individuals with this condition often experience a variety of symptoms, including numbness, tingling, aching, burning sensations, limb weakness, hyperalgesia, allodynia, and pain. The pain associated with peripheral neuropathy can manifest as superficial, deep-seated, or severe and unrelenting, often worsening at night [2]. While metabolic disorders are the most common underlying cause of extremity pain linked to peripheral neuropathy, a wide range of clinical conditions must also be considered. Among the various forms of peripheral neuropathy, diabetic peripheral neuropathy (DPN) is the most prevalent and can lead to serious complications, ranging from paresthesia to limb loss and even death [2]. Early identification and assessment of peripheral polyneuropathy symptoms are crucial to prevent neuropathic foot ulcers, which can result in significant morbidity and mortality. Poor wound healing associated with this condition can lead to limb compromise, localized or systemic infections, septicemia, and fatal outcomes [3][4][5]. DPN is typically diagnosed clinically through a detailed patient history and neurological evaluation, including assessments of small fiber sensation (using temperature changes or pinpricks), large fiber sensation (using vibration tests), and ulceration risk (using a 10 g monofilament for pressure testing). Referral to neurology and specialized tests, such as nerve conduction studies and intraepidermal nerve fiber density testing, are reserved for cases with atypical features, such as rapid symptom onset, severe motor impairment, or asymmetrical sensory abnormalities [6]. The precise cause of DPN remains unclear, though several theories have been proposed. These include metabolic, neurovascular, and autoimmune mechanisms. Additionally, mechanical compression (e.g., carpal tunnel syndrome), genetic factors, and lifestyle choices such as chronic alcohol use and smoking have been implicated. Persistent high blood glucose levels contribute to insulin resistance, which in turn promotes oxidative stress, inflammation, and cellular damage [7]. Initially, the distal sensory and autonomic nerve fibers are affected, with the damage progressing proximally over time. This leads to a gradual loss of protective sensation in the skin and joints of the feet. Management of DPN involves a multifaceted approach, including preventive measures (e.g., patient education, proper foot care, appropriate footwear, and annual foot exams), glucose control, dietary changes, weight management, and pain relief. Notably, up to half of all diabetic peripheral neuropathies may be asymmetrically present [6]. Without early recognition and the implementation of preventive foot care, patients are at a heightened risk of injury due to the loss of sensation in their feet [8][9].

**Etiology:**

Metabolic disorders are the most prevalent clinical category of etiologies responsible for extremity pain associated with peripheral neuropathy (PN). Among these, diabetes mellitus stands out as the leading cause. However, PN can arise from a variety of other underlying conditions, including alcohol use disorder [10], nutritional deficiencies such as low vitamin B12 or high vitamin B6 levels [11], and autoimmune conditions like Guillain-Barré syndrome [12]. Exposure to toxins, including chemotherapy agents and drug overdoses, has also been implicated in the development of PN [13][14][15][16]. Additionally, hereditary or genetic conditions, such as Charcot-Marie-Tooth disease, amyloidosis, and porphyria, are significant contributors [17][18][19][20][21][22]. Infections, particularly HIV, are another notable cause [23][24][25], as are inflammatory conditions like lupus and rheumatoid arthritis [26][27][28]. Other potential etiologies include hypothyroidism [29][30][31][32], malignancy, and physical trauma [33][34]. Diabetic peripheral neuropathy (DPN), a common subtype of PN, is influenced by several risk factors. Advanced age, hypertension, and peripheral vascular disease are significant contributors, alongside lifestyle factors such as smoking and excessive alcohol consumption. Dyslipidemia, poor glucose control, and long-standing diabetes further exacerbate the risk. Obesity and a positive HLA-DR3/4 genotype have also been identified as predisposing factors. These risk factors highlight the multifactorial nature of DPN, emphasizing the importance of comprehensive management strategies to mitigate its development and progression.

**Epidemiology:**

At the time of diabetes diagnosis, approximately 10% to 20% of patients are diagnosed with diabetic peripheral neuropathy (DPN). However, the prevalence of DPN increases significantly among individuals with long-standing diabetes. Studies indicate that 26% of patients develop peripheral neuropathy after 5 years, and this figure rises to 41% after 10 years. Over a lifetime, it is estimated that 50% to 66% of individuals with diabetes mellitus will develop DPN [35]. While DPN can occur in both type 1 and type 2 diabetes, it is more prevalent in type 2 diabetes due to the longer disease duration and higher rates of comorbid conditions [36]. Additionally, diabetes mellitus is the most common cause of Charcot neuroarthropathy, with an incidence ranging from 0.1% to 0.4% in the general diabetic population and as high as 29% in those with peripheral neuropathy [37]. Clinically, about half of patients with DPN may present with asymmetric sensory changes [38][39]. Obesity and genetic predisposition are significant risk factors for developing diabetes, and peripheral and autonomic neuropathies are among the leading causes of diabetes-related morbidity. Notably, patients with diabetic foot ulcers face a 2.5 times higher risk of death within 5 years compared to those without foot ulcers [40]. Furthermore, emergency department visits for diabetic foot ulcers and associated infections occur at higher rates than for conditions such as congestive heart failure, renal disease, depression, and most types of cancer [41][42]. These findings underscore the severe impact of DPN and its complications on patient outcomes and healthcare systems.

**Pathophysiology:**

Diabetic peripheral neuropathy (DPN) involves sensory, motor, and autonomic neuropathy, resulting from complex pathophysiological mechanisms. Chronic elevation of serum glucose levels leads to insulin resistance, dyslipidemia, and oxidative stress within the endoplasmic reticulum and mitochondria. These metabolic disturbances contribute to the accumulation of reactive oxygen species (ROS), which, along with inflammation, cause cellular damage. Infiltrating macrophages within peripheral nerve cells further exacerbate this damage by releasing cytokines and chemokines, promoting inflammation and subsequent nerve fiber injury [7]. Additional mechanisms implicated in peripheral nerve damage include the formation of advanced glycosylation end products (AGEs), which disrupt cellular function, and disturbances in key metabolic pathways such as the hexosamine, protein kinase C, and polyol pathways. These pathways, when dysregulated, contribute to oxidative stress and inflammation, further damaging nerve cells. Neurovascular impairment is another critical factor, characterized by poor repair processes and endothelial dysfunction, which compromise blood flow to peripheral nerves and hinder their ability to regenerate [39]. The combination of these processes leads to the progressive degeneration of nerve fibers, particularly affecting the distal sensory and autonomic nerves initially, with proximal progression over time. This results in the loss of protective sensation, particularly in the lower extremities, increasing the risk of complications such as foot ulcers and infections. The interplay of metabolic, vascular, and inflammatory pathways underscores the multifactorial nature of DPN, highlighting the need for comprehensive management strategies targeting these underlying mechanisms to prevent or mitigate nerve damage.

**Toxicokinetics:**

Transient hyperglycemia is generally well-managed by the body's compensatory physiological mechanisms and homeostatic control of blood sugar levels. However, chronically elevated serum glucose can lead to toxic effects, including the development of neuropathy. For individuals diagnosed with type 1 diabetes, stringent glucose control has been shown to significantly reduce the risk of diabetic peripheral neuropathy (DPN) by up to 78% [36]. This highlights the importance of early intervention and maintaining optimal blood glucose levels to prevent nerve damage. In contrast, for patients with long-standing hyperglycemia or those diagnosed later with type 2 diabetes, the benefits of tight glucose control are more modest, reducing the risk of DPN by only 5% to 9% [36][43]. This difference underscores the impact of disease duration and the progressive nature of metabolic dysfunction in type 2 diabetes, where prolonged exposure to high glucose levels may lead to irreversible nerve damage. These findings emphasize the need for early diagnosis and proactive management of blood glucose levels to mitigate the risk of DPN and its associated complications.

## History and Clinical:

Peripheral neuropathy is a common complication in patients with diabetes, prompting the American Diabetes Association (ADA) to recommend specific evaluation protocols. For patients with type 2 diabetes, clinicians should assess for peripheral neuropathy at the time of diagnosis, while for those with type 1 diabetes, evaluation should begin 5 years after diagnosis and continue annually. The diagnosis of peripheral neuropathy is primarily clinical, relying on a detailed history and neurological examination. This includes assessing small fiber sensation using temperature changes or pinprick tests, evaluating large fiber sensation through vibration testing, and determining ulceration risk using a 10 g monofilament for pressure testing [6].

A thorough clinical history is essential, encompassing diabetes, obesity, dyslipidemia, and hypertension, as well as a review of systems and medications to identify potential causes of diabetic peripheral neuropathy (DPN). Risk factors such as older age and poor diabetes control should also be noted. Patients often report symptoms such as burning, numbness, or tingling in the feet, which typically worsen at night. These symptoms, along with pedal paresthesias and dysesthesia, can significantly impair ambulation and daily activities. Approximately 80% of DPN patients exhibit clinical features of distal sensory peripheral neuropathy, often described as a "stocking-glove distribution," which may develop over several years [44].

The physical examination should include a comprehensive lower extremity neurological assessment, evaluating muscle strength, reflexes, and sensation. Light touch with a monofilament, vibratory sensation, and proprioception are critical components. Dermatological findings such as dry or cracked skin may indicate autonomic neuropathy, while pedal deformities like hammertoes suggest motor neuropathy [44]. Small fiber sensation is tested using temperature changes or pinpricks, while ulcer risk is assessed by the patient's ability to sense pressure. The Semmes-Weinstein 5.07 monofilament test (10 g of pressure) is commonly used, though sensory impairment may persist even after ulcer development [6]. Large fiber function is evaluated through vibratory sensation, with a 128 Hz tuning fork typically felt for 18 seconds at the dorsal hallux interphalangeal joint in healthy individuals. Loss of light touch sensation or ankle reflexes often occurs earlier in the disease, while detectable loss of protective sensation may appear later, sometimes after ulcer formation. Advanced tests like electromyography (EMG) and nerve conduction studies primarily assess large myelinated fibers, while epidermal nerve fiber density testing evaluates small unmyelinated fibers [45]. Autonomic neuropathy, another common complication of diabetes, can affect multiple organ systems. Gastrointestinal symptoms include abdominal discomfort, dysphagia, nausea, and altered bowel habits. Cardiovascular manifestations may involve hypotension, tachycardia, and syncope, while genitourinary symptoms include urinary retention and incomplete bladder emptying. Skin-related issues such as heat intolerance and excessive sweating, as well as nervous system impairments like carpal tunnel syndrome and cranial nerve dysfunction, may also occur. These diverse symptoms highlight the systemic nature of autonomic neuropathy in diabetes.

## Evaluation:

Evaluation of peripheral neuropathy typically begins with a thorough clinical assessment, and specialized testing is reserved for cases with atypical features. Neurology consultation, nerve conduction studies, and intraepidermal nerve fiber density testing are recommended only for patients presenting unusual symptoms, such as rapid onset, severe motor impairment, or asymmetrical sensory abnormalities [6]. Electromyography (EMG) and nerve conduction studies are particularly useful for evaluating severe or rapidly progressive symptoms, including motor weakness, as they provide detailed information about large, myelinated nerve fibers. For small fiber neuropathy, intraepidermal nerve fiber density (IENFD) testing is the preferred diagnostic method. This involves a skin biopsy to measure the density and morphology of nerve fibers within the epidermis, which are then compared to age-adjusted normal values. IENFD testing is especially valuable in idiopathic cases where the cause of neuropathy remains unclear [46][47]. In cases with mild or nonspecific symptoms, extensive laboratory workup may not be necessary. However, persistent or unexplained symptoms warrant further investigation. Recommended laboratory tests include serum glucose and hemoglobin A1c to assess glycemic control, complete blood count, and erythrocyte

sedimentation rate to identify inflammatory or infectious processes. Additional tests such as rapid plasma reagin (for syphilis screening), serum protein electrophoresis (to detect monoclonal gammopathies), and levels of vitamins B1, B6, and B12 (to identify nutritional deficiencies) may also be indicated. These tests help uncover underlying metabolic, nutritional, or systemic causes of neuropathy, guiding appropriate management and treatment strategies.

### **Treatment and Management:**

The management of diabetic peripheral neuropathy (DPN) involves a multifaceted approach, including preventive measures, glycemic control, lifestyle modifications, and pain management. Preventative strategies focus on patient education, proper foot care, appropriate footwear, and annual foot exams to reduce the risk of complications. Many patients with mild to moderate numbness retain protective sensation and may only require reassurance and education. Periodic follow-up is essential, and conditions such as peripheral arterial disease and radiculopathy should be ruled out. Improved glycemic control can lead to a reduction in paresthesias and dysesthesias within a year. In 2022, a treatment algorithm for painful diabetic neuropathy was proposed, categorizing therapies into conservative, pharmacological, and interventional approaches, with first-, second-, and third-line options [48]. Conservative therapy includes first-line interventions such as physical therapy, weight-bearing exercises, and Tai chi massage therapy. Second-line therapy emphasizes health management, including optimizing glucose levels, managing comorbidities, weight loss, and maintaining a healthy diet. Third-line conservative options include minimally invasive treatments like acupuncture and transcutaneous electrical nerve stimulation (TENS) [48]. Pharmacological management begins with first-line agents such as gabapentinoids (e.g., pregabalin, gabapentin) and duloxetine. Second-line agents include serotonin and norepinephrine reuptake inhibitors (e.g., venlafaxine), tricyclic antidepressants (e.g., amitriptyline), tapentadol, capsaicin patches, and lidocaine patches. Third- and fourth-line options include tramadol, opioids, and intravenous agents like lidocaine and ketamine [48].

Interventional therapies are reserved for refractory cases. First-line interventional treatment involves dorsal column spinal cord stimulation, typically using 10 kHz or tonic waveforms. Second-line options include burst spinal cord stimulation, dorsal root ganglion stimulation, and peripheral nerve stimulation. Third-line interventional therapy includes intrathecal drug delivery systems using morphine, fentanyl, hydromorphone, or ziconotide [48]. DPN can also affect other systems, requiring targeted management. Diabetic gastroparesis may be treated with erythromycin or metoclopramide, while tegaserod is available on an emergency basis due to cardiac risks [49][50][51]. Erectile dysfunction is managed with phosphodiesterase inhibitors or penile prostheses [52]. Orthostatic hypotension may respond to increased salt and fluid intake or compression stockings, with steroids as a last resort. Glycopyrrolate is used for excessive sweating but is often ineffective [53]. This comprehensive approach ensures tailored management of DPN and its systemic complications.

Alternative therapies for diabetic peripheral neuropathy (DPN) offer additional options for symptom management, though evidence supporting their efficacy varies. Omega-3 polyunsaturated fatty acids, commonly found in fish oil, have shown promise in reducing sensory loss and lowering the incidence of peripheral neuropathy. A randomized controlled trial demonstrated that omega-3 supplementation significantly increased corneal nerve fiber length in patients with dry eye disease compared to placebo, suggesting potential neuroprotective effects [54][55]. Vitamin D deficiency has been linked to an increased risk of DPN, diabetic ulcers, and cardiovascular autonomic neuropathy. A single high-dose intramuscular injection of vitamin D (600,000 IU) has been shown to improve patients' quality of life and perception of foot problems, highlighting its potential therapeutic role [56][57]. Alpha-lipoic acid supplementation has moderate evidence supporting its use for pain reduction in DPN, with minimal adverse effects reported [58][59][60]. Additionally, a prescription of medical food containing L-methyl folate, pyridoxal 5'-phosphate, and methylcobalamin has been found to improve nerve fiber density and monofilament sensation, offering a dietary management option for endothelial dysfunction [61]. However, evidence for vitamins C and E in preventing diabetic complications is limited, and there is no conclusive evidence that vitamin B12 oral supplements improve DPN symptoms [62]. Topical capsaicin cream, which depletes

substance P, may provide relief for some patients, though initial application can cause a burning sensation. For painful DPN, the capsaicin 8% patch has been shown to modestly improve pain and sleep quality when applied in serial treatments [63][64][65][66][67]. While these alternative therapies may benefit certain patients, further research is needed to establish their efficacy and safety in the management of DPN.

### **Differential Diagnosis:**

The differential diagnosis of diabetic peripheral neuropathy (DPN) includes several conditions that can present similar symptoms, necessitating careful evaluation to ensure accurate diagnosis and management. Alcohol-associated neuropathy is a common consideration, as chronic alcohol use can lead to nerve damage resembling DPN. Nutritional deficiencies, particularly those linked to vitamin B12, can also cause neuropathy, with symptoms such as numbness, tingling, and weakness. Uremic neuropathy, associated with chronic kidney disease, is another potential diagnosis, as the accumulation of toxins in renal failure can impair nerve function. Vasculitic neuropathy, resulting from inflammation of blood vessels supplying nerves, may present with asymmetric or multifocal sensory and motor deficits. Toxic metal neuropathy, caused by exposure to heavy metals such as lead or mercury, can mimic DPN and requires a thorough occupational and environmental history. These conditions highlight the importance of a comprehensive clinical assessment, including laboratory tests and detailed patient history, to distinguish DPN from other neuropathic etiologies.

### **Staging:**

The classification and staging of diabetic neuropathies are essential for understanding their clinical progression and guiding management. While various classification systems exist, most experts favor a clinical manifestation-based approach. The widely accepted classification, initially proposed by Thomas, includes the following categories: rapidly reversible hyperglycemic neuropathy, generalized symmetrical polyneuropathies (such as chronic sensorimotor and acute sensory neuropathies), autonomic neuropathy, prediabetic or impaired glucose tolerance neuropathy, and focal or multifocal neuropathies (e.g., cranial, thoracolumbar radiculoneuropathy, focal limb neuropathy, proximal motor neuropathy, and superimposed chronic inflammatory demyelinating neuropathy) [68][69]. Among these, generalized symmetrical sensorimotor polyneuropathy is the most common form of diabetic peripheral neuropathy (DPN) [70]. Staging diabetic neuropathy, as described by Dyck, provides a framework for assessing disease severity and progression. It is divided into four stages: Stage 0 indicates no evidence of neuropathy; Stage 1 represents asymptomatic neuropathy, where nerve damage is present but without clinical symptoms; Stage 2 involves symptomatic neuropathy, characterized by pain, numbness, or other sensory disturbances; and Stage 3 denotes disabling neuropathy, where nerve damage significantly impairs function and quality of life [71]. This staging system helps clinicians tailor interventions based on the severity of neuropathy, from preventive measures in early stages to more aggressive management in advanced cases.

### **Prognosis:**

The prognosis of diabetic peripheral neuropathy (DPN) is closely linked to the quality of diabetes management. Poorly controlled diabetes is associated with higher morbidity and complication rates, including skin breakdown, infections, ulcerations, and, in severe cases, amputations. These complications significantly impact patient outcomes and quality of life. Additionally, the treatment of DPN remains challenging, with less than a third of patients achieving adequate pain control. Adverse cardiac events are also common in this population, further complicating the clinical course. For most individuals with DPN, the condition leads to a diminished quality of life due to chronic pain, functional limitations, and the psychological burden of managing a progressive and debilitating condition. Early and aggressive management of diabetes, along with comprehensive care for neuropathy, is essential to improve prognosis and reduce the risk of severe complications.

### **Complications:**

Diabetic peripheral neuropathy (DPN) is associated with a range of serious complications that significantly impact patient health and quality of life. One of the most severe outcomes is the risk of amputations, often

involving the toes, foot, or leg, due to untreated ulcers, infections, or poor wound healing. Foot infections are common and can progress to systemic infections if not managed promptly. DPN also increases the risk of falls, particularly due to dizziness or loss of balance caused by sensory and motor deficits. Gastrointestinal complications, such as chronic diarrhea, failure to thrive, and dehydration, may arise from autonomic neuropathy. Chronic pain is a frequent and debilitating symptom, often resistant to treatment. Additionally, cardiovascular neuropathy, a manifestation of autonomic dysfunction, can lead to life-threatening conditions such as arrhythmias or silent myocardial infarction, contributing to increased mortality. These complications underscore the importance of early detection, comprehensive management, and preventive care to mitigate the risks associated with DPN.

### **Deterrence and Patient Education:**

Deterrence and patient education are critical components of managing diabetic peripheral neuropathy (DPN) and preventing its complications. The American Diabetes Association recommends annual comprehensive foot examinations for individuals with diabetes, along with visual foot inspections at every routine visit, typically every 3 to 4 months. Patients should be educated on the importance of daily self-monitoring of blood glucose levels and regular self-examination of their feet to identify ulcers, wounds, or skin breaks early. Adherence to a prescribed diet plan and timely medication intake are essential for maintaining glycemic control and slowing disease progression. Clinicians should emphasize the detrimental effects of alcohol consumption and smoking on peripheral neuropathy and provide support for cessation if needed. Additionally, patients should be advised to avoid wearing ill-fitting shoes, as they can increase the risk of foot injuries and ulcers. These preventive strategies, combined with patient empowerment through education, play a vital role in reducing the burden of DPN and improving long-term outcomes.

### **Other Issues:**

The lower extremities are particularly vulnerable to complications arising from repetitive microtrauma in patients with polyneuropathy. This susceptibility increases the risk of recurrent neuropathic ulcers, Charcot neuroarthropathy, and, to a lesser extent, motor neuropathy. As patients age, dystrophic nail changes further elevate the risk of subungual ulcerations, gangrene, and osteomyelitis, especially in the presence of diminished protective sensation. Regular, thorough foot examinations are crucial to identify and address these issues early. Professional foot care, including therapeutic shoes and custom insoles, has been shown to significantly reduce the incidence of lower limb amputations in individuals with diabetes mellitus. These interventions, combined with vigilant monitoring and preventive measures, are essential for mitigating the severe complications associated with diabetic peripheral neuropathy.

### **Enhancing Healthcare Outcomes:**

Enhancing healthcare outcomes for patients with diabetic neuropathy requires a collaborative, interprofessional approach due to the systemic nature of the condition and the absence of a definitive cure. Prevention is paramount, and all individuals with diabetes should receive comprehensive dietary counseling to understand which foods to consume and which to avoid. A realistic, glucose-lowering diet should be tailored to each patient's needs. Additionally, patients should be encouraged to participate in rehabilitation programs or structured exercise routines, as weight loss not only facilitates better blood glucose control but also improves blood pressure and lipid profiles. A podiatry consultation is essential to emphasize foot protection, as diabetic neuropathy significantly increases the risk of foot complications. Patients must be educated to avoid trauma, extreme temperatures, and invasive foot procedures without prior approval from their endocrinologist. A nurse specializing in diabetes management plays a critical role in patient education, ensuring individuals understand the importance of maintaining euglycemia and the broader implications of diabetes. Patients should be trained to monitor their blood glucose levels using portable glucose monitors and to recognize the signs of hypo- or hyperglycemia. Pharmacists contribute by educating patients about their medications, including their benefits, potential side effects, and the importance of adherence to prescribed therapies. Compliance with medication regimens is crucial for managing diabetes and preventing complications.

Given the systemic impact of diabetes, patients with neuropathy often develop comorbid conditions such as nephropathy and retinopathy. Therefore, referrals to nephrologists and ophthalmologists are essential for comprehensive care. Open communication among the interprofessional team, including primary care physicians, endocrinologists, podiatrists, nurses, pharmacists, and specialists, ensures that patients receive the highest standard of care with minimal morbidity. Foot and nail care nurses are particularly valuable in monitoring patients, providing ongoing education, and updating the team on the patient's condition. Pharmacists further support patient outcomes by reinforcing medication adherence and addressing any concerns related to drug therapy. Despite these efforts, outcomes for patients with diabetic neuropathy vary significantly based on treatment compliance and disease management. Noncompliant or undertreated patients often experience poorer outcomes, including skin breakdown, ulceration, infections, and, in severe cases, limb amputation. The treatment of diabetic neuropathy remains challenging, with many therapies providing only partial relief. Complete symptom resolution is rare, and the condition often leads to a diminished quality of life due to chronic pain, gastrointestinal symptoms (e.g., diarrhea, constipation), and autonomic dysfunction, such as syncopal episodes. Autonomic neuropathy, particularly cardiac involvement, is associated with higher mortality rates, ranging from 15% to 30% over ten years. The significant morbidity associated with limb amputations and other complications further underscores the need for a proactive, interprofessional approach to managing diabetic neuropathy and improving patient outcomes [70][74][75].

### **Role of Healthcare Providers:**

The role of healthcare providers in managing diabetic peripheral neuropathy (DPN) is multifaceted, requiring a collaborative, interprofessional approach to address the complex and systemic nature of the condition. Each member of the healthcare team plays a distinct yet interconnected role in ensuring optimal patient outcomes. Primary care physicians and endocrinologists are typically at the forefront of diabetes management, responsible for diagnosing DPN, initiating treatment, and coordinating care with other specialists. They focus on achieving glycemic control through medication management, lifestyle modifications, and regular monitoring of blood glucose levels. These providers also educate patients about the importance of adherence to treatment plans and the potential complications of poorly managed diabetes, including neuropathy.

Nurses, particularly those specializing in diabetes care, are essential in providing patient education and ongoing support. They teach patients how to monitor blood glucose levels, recognize symptoms of hypo- or hyperglycemia, and perform daily foot inspections to identify early signs of ulcers or infections. Nurses also play a critical role in reinforcing the importance of lifestyle changes, such as maintaining a healthy diet, engaging in regular physical activity, and avoiding smoking and excessive alcohol consumption. Their continuous interaction with patients allows them to monitor progress, address concerns, and provide timely interventions to prevent complications. Podiatrists are integral to the management of DPN, as the condition significantly increases the risk of foot-related complications. They conduct regular foot examinations, provide guidance on proper footwear, and manage conditions such as neuropathic ulcers and Charcot neuroarthropathy. Podiatrists also educate patients on foot care practices, including the importance of avoiding trauma and extreme temperatures, and they perform necessary procedures to prevent infections or amputations. Their expertise is crucial in reducing the morbidity associated with diabetic foot complications. Pharmacists contribute by ensuring patients understand their medications, including their mechanisms of action, benefits, and potential side effects. They play a key role in optimizing medication regimens, addressing drug interactions, and promoting adherence to therapy. Pharmacists also provide education on over-the-counter products, such as topical creams for neuropathic pain, and advise on the safe use of supplements that may complement conventional treatments.

Specialists, including nephrologists and ophthalmologists, are often involved in the care of patients with DPN due to the high prevalence of comorbid conditions such as diabetic nephropathy and retinopathy. These providers monitor organ-specific complications and implement targeted interventions to preserve function and prevent progression. For example, nephrologists manage kidney health through medication adjustments and dialysis if necessary, while ophthalmologists conduct regular eye exams to detect and treat



retinopathy early. Finally, mental health professionals and physical therapists may also be part of the interprofessional team. Mental health providers address the psychological burden of living with a chronic condition, offering support for anxiety, depression, and coping strategies. Physical therapists assist with mobility issues, designing exercise programs to improve strength, balance, and coordination, thereby reducing the risk of falls and enhancing overall quality of life. Effective communication and collaboration among healthcare providers are essential to delivering comprehensive, patient-centered care. Regular team meetings, shared electronic health records, and clear care plans ensure that all providers are aligned in their approach, minimizing gaps in care and optimizing outcomes for patients with DPN. By leveraging the expertise of each team member, healthcare providers can address the multifaceted challenges of DPN, improve patient adherence, and reduce the risk of severe complications, ultimately enhancing the quality of life for individuals living with this condition.

## **Conclusion:**

Diabetic peripheral neuropathy (DPN) is a significant and often debilitating complication of diabetes mellitus, affecting a large proportion of diabetic patients over their lifetime. Its impact on quality of life and healthcare costs is substantial, making early identification and management crucial. The pathophysiology of DPN involves metabolic dysfunction, oxidative stress, inflammation, and neurovascular impairment. These processes contribute to progressive nerve fiber degeneration, leading to sensory loss and increased risk of foot ulcers and lower limb amputations. Chronic hyperglycemia is a primary driver of nerve damage, making glycemic control a key preventive measure. However, while strict glucose management in type 1 diabetes can significantly reduce DPN risk, its impact in type 2 diabetes is less pronounced. Diagnosis is primarily clinical, relying on patient history and neurological examination. Standardized tests, such as monofilament testing and vibration perception, aid in assessing sensory deficits. In complex or atypical cases, specialized diagnostic tools like nerve conduction studies and skin biopsy for intraepidermal nerve fiber density assessment may be required. Management of DPN involves a multifaceted approach. Preventive strategies, including routine foot examinations, patient education, and appropriate footwear, play a crucial role in reducing complications. Pharmacological treatment focuses on symptom control and includes medications such as anticonvulsants, antidepressants, and analgesics. Emerging therapies targeting oxidative stress and inflammatory pathways hold promise for future treatment advancements. Healthcare professionals must emphasize early detection and comprehensive care to minimize the impact of DPN. Integrating glycemic control with lifestyle interventions, pain management, and foot care programs can significantly improve patient outcomes. Further research is needed to explore novel therapeutic approaches and refine existing management protocols. DPN remains a major challenge in diabetes care, but with proactive strategies, the burden of this condition can be mitigated, ultimately enhancing patient well-being and reducing healthcare system costs.

## **References:**

1. Wang Y, Li W, Peng W, Zhou J, Liu Z. Acupuncture for postherpetic neuralgia: Systematic review and meta-analysis. *Medicine (Baltimore)*. 2018 Aug;97(34):e11986.
2. Çakici N, Fakkal TM, van Neck JW, Verhagen AP, Coert JH. Systematic review of treatments for diabetic peripheral neuropathy. *Diabet Med*. 2016 Nov;33(11):1466-1476.
3. Dewanjee S, Das S, Das AK, Bhattacharjee N, Dihingia A, Dua TK, Kalita J, Manna P. Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets. *Eur J Pharmacol*. 2018 Aug 15;833:472-523.
4. Alavi A, Sibbald RG, Mayer D, Goodman L, Botros M, Armstrong DG, Woo K, Boeni T, Ayello EA, Kirsner RS. Diabetic foot ulcers: Part I. Pathophysiology and prevention. *J Am Acad Dermatol*. 2014 Jan;70(1):1.e1-18; quiz 19-20.
5. Vinik AI, Casellini C, Névoret ML. Alternative Quantitative Tools in the Assessment of Diabetic Peripheral and Autonomic Neuropathy. *Int Rev Neurobiol*. 2016;127:235-85.
6. Elafros MA, Andersen H, Bennett DL, Savelieff MG, Viswanathan V, Callaghan BC, Feldman EL. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. *Lancet Neurol*. 2022 Oct;21(10):922-936.

7. Baum P, Toyka KV, Blüher M, Kosacka J, Nowicki M. Inflammatory Mechanisms in the Pathophysiology of Diabetic Peripheral Neuropathy (DN)-New Aspects. *Int J Mol Sci.* 2021 Oct 07;22(19)
8. Vinik AI, Casellini C, Parson HK, Colberg SR, Nevoret ML. Cardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events. *Front Neurosci.* 2018;12:591.
9. Sloan G, Shillo P, Selvarajah D, Wu J, Wilkinson ID, Tracey I, Anand P, Tesfaye S. A new look at painful diabetic neuropathy. *Diabetes Res Clin Pract.* 2018 Oct;144:177-191.
10. Julian T, Glasgow N, Syeed R, Zis P. Alcohol-related peripheral neuropathy: a systematic review and meta-analysis. *J Neurol.* 2019 Dec;266(12):2907-2919.
11. Gwathmey KG, Grogan J. Nutritional neuropathies. *Muscle Nerve.* 2020 Jul;62(1):13-29.
12. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. *Lancet.* 2016 Aug 13;388(10045):717-27.
13. Freund PR, Wright T, Margolin EA. Toxic Optic Neuropathy From Quinine Overdose. *J Neuroophthalmol.* 2020 Jun;40(2):258-261
14. Guala A, Folgori G, Silvestri M, Barbaglia M, Danesino C. Vitamin B6 Neonatal Toxicity. *Case Rep Pediatr.* 2022;2022:3171351.
15. Malet L, Dayot L, Moussy M, de la Gastine B, Goutelle S. [Peripheral neuropathy with hypervitaminosis B6 caused by self-medication]. *Rev Med Interne.* 2020 Feb;41(2):126-129.
16. Ko JU, Seo H, Lee GJ, Park D. Bilateral sciatic neuropathy with severe rhabdomyolysis following venlafaxine overdose: A case report. *Medicine (Baltimore).* 2018 Sep;97(37):e12220.
17. Ly KI, Blakeley JO. The Diagnosis and Management of Neurofibromatosis Type 1. *Med Clin North Am.* 2019 Nov;103(6):1035-1054.
18. Jani-Acsadi A, Ounpuu S, Pierz K, Acsadi G. Pediatric Charcot-Marie-Tooth disease. *Pediatr Clin North Am.* 2015 Jun;62(3):767-86.
19. Freeman R. Autonomic Peripheral Neuropathy. *Continuum (Minneap Minn).* 2020 Feb;26(1):58-71.
20. Kaku M, Berk JL. Neuropathy Associated with Systemic Amyloidosis. *Semin Neurol.* 2019 Oct;39(5):578-588.
21. Gandhi Mehta RK, Caress JB, Rudnick SR, Bonkovsky HL. Porphyric neuropathy. *Muscle Nerve.* 2021 Aug;64(2):140-152.
22. Gerischer LM, Scheibe F, Nümann A, Köhnlein M, Stölzel U, Meisel A. Acute porphyrias - A neurological perspective. *Brain Behav.* 2021 Nov;11(11):e2389.
23. Abrams RMC, Simpson DM, Navis A, Jette N, Zhou L, Shin SC. Small fiber neuropathy associated with SARS-CoV-2 infection. *Muscle Nerve.* 2022 Apr;65(4):440-443.
24. Saif DS, Ibrahim RA, Eltabl MA. Prevalence of peripheral neuropathy and myopathy in patients post-COVID-19 infection. *Int J Rheum Dis.* 2022 Nov;25(11):1246-1253.
25. Benstead TJ, Chalk CH, Parks NE. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection. *Cochrane Database Syst Rev.* 2014 Dec 20;2014(12):CD010404.
26. Ferro JM, Oliveira Santos M. Neurology of inflammatory bowel disease. *J Neurol Sci.* 2021 May 15;424:117426.
27. García-Cabo C, Morís G. Peripheral neuropathy: an underreported neurologic manifestation of inflammatory bowel disease. *Eur J Intern Med.* 2015 Sep;26(7):468-75.
28. Seeliger T, Prenzler NK, Ginge S, Seeliger B, Körner S, Thiele T, Bönig L, Sühs KW, Witte T, Stangel M, Skripuletz T. Neuro-Sjögren: Peripheral Neuropathy With Limb Weakness in Sjögren's Syndrome. *Front Immunol.* 2019;10:1600.
29. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. *Pain.* 2014 Dec;155(12):2461-2470.
30. Sałat K. Chemotherapy-induced peripheral neuropathy-part 2: focus on the prevention of oxaliplatin-induced neurotoxicity. *Pharmacol Rep.* 2020 Jun;72(3):508-527.
31. Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: A current review. *Ann Neurol.* 2017 Jun;81(6):772-781.

32. Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. *Int J Mol Sci*. 2019 Mar 22;20(6)
33. Taylor CA, Braza D, Rice JB, Dillingham T. The incidence of peripheral nerve injury in extremity trauma. *Am J Phys Med Rehabil*. 2008 May;87(5):381-5.
34. Noland SS, Bishop AT, Spinner RJ, Shin AY. Adult Traumatic Brachial Plexus Injuries. *J Am Acad Orthop Surg*. 2019 Oct 01;27(19):705-716.
35. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, Wilson DM, O'Brien PC, Melton LJ, Service FJ. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. *Neurology*. 1993 Apr;43(4):817-24.
36. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. *Diabetes Care*. 2017 Jan;40(1):136-154.
37. Hjelm LR. Diabetes Mellitus: An Overview in Relationship to Charcot Neuroarthropathy. *Clin Podiatr Med Surg*. 2022 Oct;39(4):535-542.
38. Djibril AM, Mossi EK, Djagadou AK, Balaka A, Tchamdja T, Moukaila R. [Epidemiological, diagnostic, therapeutic and evolutionary features of diabetic foot: a study conducted at the Medico-surgical Clinic, University Hospital Sylvanus Olympio in Lomé]. *Pan Afr Med J*. 2018;30:4.
39. Ghotaslou R, Memar MY, Alizadeh N. Classification, microbiology and treatment of diabetic foot infections. *J Wound Care*. 2018 Jul 02;27(7):434-441.
40. Schröder K, Szendroedi J, Benthin A, Gontscharuk V, Ackermann P, Völker M, Steingrube N, Nowotny B, Ziegler D, Müssig K, Geerling G, Kuß O, Roden M, Guthoff R., GDS Cohort. German Diabetes Study - Baseline data of retinal layer thickness measured by SD-OCT in early diabetes mellitus. *Acta Ophthalmol*. 2019 Mar;97(2):e303-e307.
41. Moțățăianu A, Maier S, Bajko Z, Voidazan S, Bălașa R, Stoian A. Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients. *BMC Neurol*. 2018 Aug 27;18(1):126.
42. Doria M, Viadé J, Palomera E, Pérez R, Lladó M, Costa E, Huguet T, Reverter JL, Serra-Prat M, Franch-Nadal J, Mauricio D. Short-term foot complications in Charcot neuroarthropathy: A retrospective study in tertiary care centres in Spain. *Endocrinol Diabetes Nutr (Engl Ed)*. 2018 Nov;65(9):479-485.
43. Giri B, Dey S, Das T, Sarkar M, Banerjee J, Dash SK. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity. *Biomed Pharmacother*. 2018 Nov;107:306-328.
44. Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. *Nat Rev Endocrinol*. 2021 Jul;17(7):400-420.
45. Sène D. Small fiber neuropathy: Diagnosis, causes, and treatment. *Joint Bone Spine*. 2018 Oct;85(5):553-559.
46. Chedid V, Brandler J, Vijayvargiya P, Park SY, Szarka LA, Camilleri M. Characterization of Upper Gastrointestinal Symptoms, Gastric Motor Functions, and Associations in Patients with Diabetes at a Referral Center. *Am J Gastroenterol*. 2019 Jan;114(1):143-154.
47. Petropoulos IN, Ponirakis G, Khan A, Almuhanadi H, Gad H, Malik RA. Diagnosing Diabetic Neuropathy: Something Old, Something New. *Diabetes Metab J*. 2018 Aug;42(4):255-269.
48. D'Souza RS, Barman R, Joseph A, Abd-Elseyed A. Evidence-Based Treatment of Painful Diabetic Neuropathy: a Systematic Review. *Curr Pain Headache Rep*. 2022 Aug;26(8):583-594.
49. Shakhathreh M, Jehangir A, Malik Z, Parkman HP. Metoclopramide for the treatment of diabetic gastroparesis. *Expert Rev Gastroenterol Hepatol*. 2019 Aug;13(8):711-721.
50. Frazee LA, Mauro LS. Erythromycin in the Treatment of Diabetic Gastroparesis. *Am J Ther*. 1994 Dec;1(4):287-295.
51. Stevens JE, Jones KL, Rayner CK, Horowitz M. Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives. *Expert Opin Pharmacother*. 2013 Jun;14(9):1171-86.

52. Mobley DF, Khera M, Baum N. Recent advances in the treatment of erectile dysfunction. *Postgrad Med J*. 2017 Nov;93(1105):679-685.
53. Palma JA, Kaufmann H. Management of Orthostatic Hypotension. *Continuum (Minneap Minn)*. 2020 Feb;26(1):154-177.
54. Zhang AC, De Silva MEH, MacIsaac RJ, Roberts L, Kamel J, Craig JP, Busija L, Downie LE. Omega-3 polyunsaturated fatty acid oral supplements for improving peripheral nerve health: a systematic review and meta-analysis. *Nutr Rev*. 2020 Apr 01;78(4):323-341.
55. Chinnery HR, Naranjo Golborne C, Downie LE. Omega-3 supplementation is neuroprotective to corneal nerves in dry eye disease: a pilot study. *Ophthalmic Physiol Opt*. 2017 Jul;37(4):473-481.
56. Putz Z, Tordai D, Hajdú N, Vági OE, Kempler M, Békeffy M, Körei AE, Istenes I, Horváth V, Stoian AP, Rizzo M, Papanas N, Kempler P. Vitamin D in the Prevention and Treatment of Diabetic Neuropathy. *Clin Ther*. 2022 May;44(5):813-823.
57. Alam U, Fawwad A, Shaheen F, Tahir B, Basit A, Malik RA. Improvement in Neuropathy Specific Quality of Life in Patients with Diabetes after Vitamin D Supplementation. *J Diabetes Res*. 2017;2017:7928083.
58. Esposito C, Ugo Garzarella E, Santarcangelo C, Di Minno A, Dacrema M, Sacchi R, Piccinocchi G, Piccinocchi R, Daglia M. Safety and efficacy of alpha-lipoic acid oral supplementation in the reduction of pain with unknown etiology: A monocentric, randomized, double-blind, placebo-controlled clinical trial. *Biomed Pharmacother*. 2021 Dec;144:112308.
59. Jeffrey S, Samraj PI, Raj BS. The Role of Alpha-lipoic Acid Supplementation in the Prevention of Diabetes Complications: A Comprehensive Review of Clinical Trials. *Curr Diabetes Rev*. 2021;17(9):e011821190404.
60. Retraction. Alpha-lipoic acid supplementation and diabetes. *Nutr Rev*. 2012 Aug;70(8):482.
61. Fonseca VA, Lavery LA, Thethi TK, Daoud Y, DeSouza C, Ovalle F, Denham DS, Bottiglieri T, Sheehan P, Rosenstock J. Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. *Am J Med*. 2013 Feb;126(2):141-9.
62. Jayabalan B, Low LL. Vitamin B supplementation for diabetic peripheral neuropathy. *Singapore Med J*. 2016 Feb;57(2):55-9.
63. Krishnasamy S, Abell TL. Diabetic Gastroparesis: Principles and Current Trends in Management. *Diabetes Ther*. 2018 Jul;9(Suppl 1):1-42.
64. Garcia-Klepzig JL, Sánchez-Ríos JP, Manu C, Ahluwalia R, Lüdemann C, Meloni M, Lacopi E, De Buruaga VR, Bouillet B, Vouillarmet J, Lázaro-Martínez JL, Van Acker K. Perception of diabetic foot ulcers among general practitioners in four European countries: knowledge, skills and urgency. *J Wound Care*. 2018 May 02;27(5):310-319.
65. Iqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M, Cuthbertson DJ, Lim J, Malik RA, Alam U. Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy. *Clin Ther*. 2018 Jun;40(6):828-849.
66. Simpson DM, Robinson-Papp J, Van J, Stoker M, Jacobs H, Snijder RJ, Schregardus DS, Long SK, Lambourg B, Katz N. Capsaicin 8% Patch in Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study. *J Pain*. 2017 Jan;18(1):42-53.
67. Vinik AI, Perrot S, Vinik EJ, Pazdera L, Jacobs H, Stoker M, Long SK, Snijder RJ, van der Stoep M, Ortega E, Katz N. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. *BMC Neurol*. 2016 Dec 06;16(1):251.
68. Boulton AJ. Diabetic neuropathy: classification, measurement and treatment. *Curr Opin Endocrinol Diabetes Obes*. 2007 Apr;14(2):141-5.
69. Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. *Diabetes*. 1997 Sep;46 Suppl 2:S54-7.
70. Zafeiri M, Tsioutis C, Kleinaki Z, Manolopoulos P, Ioannidis I, Dimitriadis G. Clinical Characteristics of Patients with co-Existent Diabetic Peripheral Neuropathy and Depression: A Systematic Review. *Exp Clin Endocrinol Diabetes*. 2021 Feb;129(2):77-85.

71. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. *Muscle Nerve*. 1988 Jan;11(1):21-32.
72. Ferraresi R, Casini A, Caminiti M, Losurdo F, Clerici G. [Multidisciplinary approach to diabetic foot: a challenge of expertises]. *G Ital Cardiol (Rome)*. 2018 Sep;19(9):495-503.
73. Jiménez S, Rubio JA, Álvarez J, Lázaro-Martínez JL. Analysis of recurrent ulcerations at a multidisciplinary diabetic Foot unit after implementation of a comprehensive Foot care program. *Endocrinol Diabetes Nutr (Engl Ed)*. 2018 Oct;65(8):438.e1-438.e10.
74. Edwards RA, Bonfanti G, Grugni R, Manca L, Parsons B, Alexander J. Predicting Responses to Pregabalin for Painful Diabetic Peripheral Neuropathy Based on Trajectory-Focused Patient Profiles Derived from the First 4 Weeks of Treatment. *Adv Ther*. 2018 Oct;35(10):1585-1597.
75. Bodman, M. A., & Varacallo, M. (2023). Peripheral diabetic neuropathy. In *StatPearls [Internet]*. StatPearls Publishing.

اعتلال الأعصاب الطرفية السكري: مراجعة محدثة لمقدمي الرعاية الصحية

#### الملخص:

الخلفية: يُعد اعتلال الأعصاب الطرفية السكري (DPN) من المضاعفات الشائعة لداء السكري، مما يؤدي إلى اضطرابات حسية وحركية وذاتية. يظهر على شكل ألم، وخدر، وتنميل، وفقدان تدريجي للإحساس الوقائي، مما يزيد من خطر الإصابة بقرح القدم وبتر الأطراف. لا تزال الآلية المرضية الدقيقة غير واضحة، ولكن تسهم العوامل الأيضية والوعائية العصبية والالتهابية في تلف الأعصاب.

الهدف: تقديم مراجعة محدثة لمقدمي الرعاية الصحية حول علم الأوبئة والفيزيولوجيا المرضية وتشخيص وإدارة اعتلال الأعصاب الطرفية السكري، مع التركيز على استراتيجيات الاكتشاف المبكر والوقاية.

المنهجية: تم إجراء مراجعة شاملة للأدبيات باستخدام دراسات محكمة حول اعتلال الأعصاب السكري. تم تحليل البيانات الوبائية وعوامل الخطر والأساليب التشخيصية والتدخلات العلاجية لتقديم تحديث قائم على الأدلة.

النتائج: يؤثر اعتلال الأعصاب الطرفية السكري على 50-66% من مرضى السكري خلال حياتهم. يعتمد التشخيص المبكر على التقييم السريري، بما في ذلك اختبارات الألياف العصبية الصغيرة والكبيرة واختبار المونوفيلامنت. تساهم فرط سكر الدم المستمر، والإجهاد التأكسدي، والعمليات الالتهابية في تلف الأعصاب. يؤدي التحكم الصارم في مستوى السكر في الدم إلى تقليل خطر الإصابة باعتلال الأعصاب الطرفية السكري بنسبة تصل إلى 78% في مرضى السكري من النوع الأول، بينما يكون التأثير أقل في مرضى السكري من النوع الثاني. يمكن للإدارة متعددة الجوانب، بما في ذلك التحكم في نسبة السكر في الدم، وتعديلات نمط الحياة، والعناية بالقدم، والعلاج العرضي، أن تقلل من المضاعفات وتحسن نتائج المرضى.

الخلاصة: يُعد اعتلال الأعصاب الطرفية السكري سببًا رئيسيًا للمراضة والإعاقة لدى مرضى السكري. يُعد التشخيص المبكر والتدخل السريع أمرًا بالغ الأهمية لمنع المضاعفات. تتطلب الإدارة الشاملة استراتيجيات تشمل التحكم في نسبة السكر في الدم، وتنقيف المرضى، والعلاجات الدوائية المستهدفة لتقليل عبء المرض وتحسين جودة الحياة.

الكلمات المفتاحية: اعتلال الأعصاب الطرفية السكري، داء السكري، الألم العصبي، التحكم في سكر الدم، قرح القدم، الفحص العصبي.